Bristol-Myers Settlement: A Strong Warning To Joint Venturers
In yet another resolution with a life sciences company of alleged violations of the Foreign Corrupt Practices Act, the U.S. Securities and Exchange Commission took last week's settlement with New York-based...To view the full article, register now.
Already a subscriber? Click here to view full article